Orforglipron
As of the edition of 20 October 2026, Orforglipron is a small molecule: marketed, first approved in 2026 (US); acts on GLP1R; US protection ends in 2037.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Foundayo
- First approved
- 1 April 2026 (US)
- Approvals on record
- 6 in 1 region
- Holder of the most recent approval
- Eli Lilly
- Registered trials
- 51, 0 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive; Bones, joints and muscles
US protection
US protection ends in 2037.
The last listed US drug-substance patent ends in 2037. The application that gives this date is held by Eli Lilly.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product12 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 12 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GLP1R | Glucagon-like peptide 1 receptor | P43220 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 21 | 21 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 27 | 10 | 17 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 51 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Originator and Lead sponsor of trials | 2019 to now |